Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March ...

Survival rates for metastatic lung cancer are estimates ... health genetic changes in the cancer cells subtype of NSCLC how effective treatment is Survival rates are also constantly changing.

Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.